Investing2 天
Fortress Biotech partners with Partex for AI-driven drug discovery
Meanwhile, Fortress Biotech, Mustang Bio’s parent company, revealed that the FDA has extended the review period for the New Drug Application of CUTX-101 to September 30, 2025. This extension is ...
optometryadvisor3 天
January 2025 Recap: Drug Pipeline Updates
Click on the status to view our full coverage. CUTX-101 (copper histidinate; Fortress Biotech and Cyprium Therapeutics) Copper replacement therapy Treatment of Menkes disease. Accepted for Priority ...
Yahoo Finance2 天
Fortress Biotech, Inc. (FBIO)
After hours: March 18 at 5:45:28 PM EDT Loading Chart for FBIO ...
Investing2 天
Fortress Biotech partners with Partex for AI-driven drug discovery
Meanwhile, Fortress Biotech, Mustang Bio’s parent company, revealed that the FDA has extended the review period for the New Drug Application of CUTX-101 to September 30, 2025. This extension is a ...
Fortress Biotech与Partex合作开展AI驱动的药物研发
法兰克福和迈阿密讯 - 市值4,610万美元、过去十二个月收入增长31.5%的生物制药公司Fortress Biotech, Inc. (NASDAQ: FBIO )宣布与Partex NV建立战略合作，利用人工智能 (AI)技术搜索和评估潜在的生物制药化合物，以进行收购或授权。根据 InvestingPro ...
Business Insider2 天
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset ...
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a ...